Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 3:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Morbid Obesity, Metabolic Disease
Interventions
Laparoscopic Roux-en-Y Gastric Bypass
Procedure
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
10
States / cities
Irvine, California • Orange, California • Atlanta, Georgia + 6 more
Conditions
Liver Disease
Interventions
Not listed
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 100 Years
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2021
U.S. locations
1
States / cities
San Diego, California
Conditions
Nonalcoholic Steatohepatitis
Interventions
L-alanine
Drug
Lead sponsor
Keith D Lindor, M.D.
Other
Eligibility
18 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Nonalcoholic Steatohepatitis
Interventions
SEL, Placebo to match SEL 6 mg, Placebo to match SEL 18 mg
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
808 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
124
States / cities
Chandler, Arizona • Phoenix, Arizona • Tucson, Arizona + 95 more
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Online App Weight Loss Programs on Liver Health in Obese Adults

NCT05015491
Conditions
NASH, Fatty Liver, NAFLD, Weight Loss
Interventions
Noom Healthy Weight Program
Behavioral
Lead sponsor
Noom Inc.
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Chandler, Arizona
Conditions
Non-Alcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis (NASH)
Interventions
Positron Emission Tomography (PET) on EXPLORER, Magnetic Resonance Imaging, Echocardiogram and Electrocardiogram, Blood test
Radiation · Diagnostic Test
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Sacramento, California
Conditions
Nonalcoholic Steatohepatitis (NASH)
Interventions
Firsocostat, Fenofibrate
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
5
States / cities
Tustin, California • Miami, Florida • Orlando, Florida + 2 more
Conditions
Nonalcoholic Steatohepatitis (NASH)
Interventions
CS0159 (Linafexor)
Drug
Lead sponsor
Cascade Pharmaceuticals, Inc
Other
Eligibility
18 Years to 75 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
17
States / cities
Gardena, California • Huntington Park, California • Panorama City, California + 13 more
Conditions
Lysosomal Acid Lipase Deficiency, Wolman Disease
Interventions
Sebelipase alfa (SBC-102)
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
Up to 24 Months
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Irvine, California
Conditions
NAFLD
Interventions
Usual diet and physical activity
Other
Lead sponsor
Yale University
Other
Eligibility
12 Years to 18 Years
Enrollment
260 participants
Timeline
2021 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD, MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis), MetALD
Interventions
Not listed
Lead sponsor
HRI-MAIL-NIT
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,689 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
8
States / cities
Chandler, Arizona • Peoria, Arizona • Tucson, Arizona + 4 more
Conditions
Non-Alcoholic Fatty Liver Disease, Non Alcoholic Steatohepatitis
Interventions
NAFLD/NASH
Other
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years and older
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
MET642, Placebo
Drug
Lead sponsor
Metacrine, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Non Alcoholic Fatty Liver
Interventions
Omega-3, Olive oil
Dietary Supplement
Lead sponsor
Pronova BioPharma
Industry
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
7
States / cities
Hialeah, Florida • Lake Worth, Florida • Lauderdale Lakes, Florida + 3 more
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Role of Immune System in Obesity-related Inflammation and Cardiometabolic Risk

NCT01104220
Conditions
Non-alcoholic Fatty Liver Disease, Metabolic Syndrome, Metabolically Abnormal Obesity, Metabolically Normal Obesity, Obesity
Interventions
Weight loss
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 90 Years
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Hepatic Steatosis
Interventions
VLX103
Drug
Lead sponsor
Gyongyi Szabo
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Worcester, Massachusetts
Conditions
Non-alcoholic Steatohepatitis
Interventions
NNC0194 0499 50 mg/mL, Placebo (NNC0194-0499), Semaglutide 3 mg/mL, Semaglutide placebo, NNC0174 0833 10 mg/mL, NNC0174 0833 placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
Not listed
Enrollment
698 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
70
States / cities
Huntsville, Alabama • Chandler, Arizona • Peoria, Arizona + 59 more
Conditions
Non-alcoholic Steatohepatitis
Interventions
Semaglutide, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
130
States / cities
Huntsville, Alabama • Chandler, Arizona • Peoria, Arizona + 100 more
Conditions
Non-Alcoholic Steatohepatitis
Interventions
BMS-986036, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
21 Years to 75 Years
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
17
States / cities
Rialto, California • San Diego, California • Indianapolis, Indiana + 14 more
Conditions
Intestinal Failure-associated Liver Disease
Interventions
Not listed
Lead sponsor
Protara Therapeutics
Industry
Eligibility
12 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
10
States / cities
Los Angeles, California • Kissimmee, Florida • Chicago, Illinois + 7 more
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Efinopegdutide in Participants With Hepatic Impairment (MK-6024-014)

NCT06052566
Conditions
Non-alcoholic Steatohepatitis, Hepatic Impairment
Interventions
Efinopegdutide
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
4
States / cities
Miami, Florida • Tampa, Florida • San Antonio, Texas
Conditions
Nonalcoholic Steatohepatitis (NASH)
Interventions
Cilofexor, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 45 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Miami, Florida
Conditions
Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Interventions
Resmetirom therapy, Comprehensive nutritional intervention, Standard dietary support
Drug · Behavioral
Lead sponsor
City University of New York
Other
Eligibility
18 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New York, New York
Conditions
Healthy
Interventions
No intervention
Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
830 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
3
States / cities
Hollywood, Florida • Lenexa, Kansas • San Antonio, Texas